Evaluation and Management of Metabolic Bone Disease in Kidney Transplant Recipients

NACompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

December 12, 2018

Primary Completion Date

December 2, 2021

Study Completion Date

December 2, 2021

Conditions
Skeletal AnomaliesKidney Transplant; Complications
Interventions
DIAGNOSTIC_TEST

measurements to evaluate metabolic bone disease

The participants will be evaluated for a) Mineral metabolism: blood calcium, phosphorus, PTH, 25(OH) vitamin D; b) Bone turnover markers: bone-specific alkaline phosphatase, cross-linked C-telopeptide of type I collagen (CTx), and N-terminal propeptide of type I collagen (PINP); c) Bone Mineral Density using a Dual energy x-ray absorptiometry which is the standard method by which bone mass is measured clinically. The bone mass at the lumbar spine, wrist, hip and total body bone mass at 3, and 18 months.

DIAGNOSTIC_TEST

standard care

Blood tests (Ca, Phos, PTH- mineral lab, 25OHVitD);Pregnancy Test (if applicable); dual energy X-ray absorptiometry (DXA); Bone Biopsy only if clinically indicated; treatment as clinically indicated.

Trial Locations (1)

06510

Yale Transplantation Center/Yale-New Haven Hospital, New Haven

All Listed Sponsors
lead

Yale University

OTHER

NCT03958409 - Evaluation and Management of Metabolic Bone Disease in Kidney Transplant Recipients | Biotech Hunter | Biotech Hunter